Pursuant to Regulation 30 of the Listing Regulations, please find enclosed Press Release on theAudited Financial Results (Standalone and Consolidated) for the quarter and the financial yearended 31st March, 2026.
WOCKPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.1 pts more than Nifty Smallcap 250 and 8.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Wockhardt reported a strong turnaround in FY26 with profit before tax of Rs. 238 crore compared to a loss of Rs. 16 crore in the previous year. Full-year revenue grew 11% to Rs. 3,373 crore, while EBITDA surged 51% to Rs. 630 crore with margins expanding from 13.8% to 18.7%. Q4 was particularly strong with revenue up 30% and EBITDA up 147% year-on-year. Exceptional items of Rs. 85 crore include restructuring charges, US entity liquidation costs, and a net credit from a settlement with Dr. Reddy's. Biotech operations delivered 27% growth for the year at Rs. 697 crore, driven by emerging markets. Novel antibiotics Zaynich received EMA Accelerated Assessment and is progressing through US FDA and EU EMA reviews.
The company has returned to sustained profitability with strong margin expansion and revenue growth, signaling an operational turnaround. The exceptional items include one-time charges but are partially offset by a settlement credit, and the expansion in EBITDA margins is a positive signal for shareholders.